Abstract
BackgroundTreatment of pulmonary exacerbations (PEx) in cystic fibrosis (CF) varies widely with no consensus on management practices or best indicators of therapeutic success. To design trials evaluating PEx treatment factors,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have